Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2013 Dec 19;13(2):426–432. doi: 10.1158/1535-7163.MCT-13-0633

Figure 2.

Figure 2

Enhanced delivery of liposomal daunorubicin based on PIT-induced SUPR effects. (A) In vivo fluorescence images of Pan-IR700 (green). PIT was performed only on the right-side tumor with the left-side tumor serving as a control. (B) Liposomal daunorubicin (yellow) preferentially accumulated in PIT-treated mixed tumors (red circles) at 30 min post injection of liposomal daunorubicin, but did not accumulate in no NIR light exposure control tumors (blue circles) growing in the same mice. (C) Dynamic fluorescence intensity curves show that daunorubicin accumulated and was retained by PIT-treated tumors selectively. ‘Back’ indicates the fluorescence in the back representing background signal. Data are means ± s.e.m. (n=3). (D) Intratumoral distribution of daunorubicin. Daunorubicin was broadly and homogeneously distributed post-PIT encircling the surviving tumor cells (Balb/DsRed and A431). DsRed: red, DX (daunorubicin): yellow, IR700: green. Scale bars: 100 μm.